Icon reported revenue of $2.06 billion in the second quarter, up 1.2% from the prior-year period. Net business wins in the quarter were $3.1 billion, and the backlog increased 3% sequentially to $23.4 billion. Management maintained its 2026 guidance, including revenue of $8 billion at the midpoint.
If biotech funding recovers and clinical trial starts increase, this could improve bookings growth, lower cancellations, and return to mid‑single‑digit revenue growth.
Drawbacks to biotech funding or declines in outsourcing penetration rates could have a material impact on Icon's growth.
|
Metric
|
ICLR
|
FTRE
|
MEDP
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.98 | 130.23 | 33.91 |
Price/Book Value | 1.34 | 3.16 | 37.22 |
Price/Sales | 1.52 | 0.61 | 5.99 |
Price/Cash Flow | 13.19 | 30.99 | 26.37 |
|
Metric
|
ICLR
|
FTRE
|
MEDP
|
|---|---|---|---|
Quick Ratio | 0.92 | 0.85 | 0.66 |
Current Ratio | 0.95 | 0.96 | 0.73 |
Interest Coverage | 1.53 | 0.08 | — |
|
Metric
|
ICLR
|
FTRE
|
MEDP
|
|---|---|---|---|
Return on Assets (Normalized) | 3.91% | 2.15% | 26.82% |
Return on Equity (Normalized) | 6.87% | 10.56% | 130.01% |
Return on Invested Capital (Normalized) | 6.21% | 7.32% | 97.04% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|%@WFD<k | LOCK|N%# | $218B | |||
| Danaher Corp
DHR
| LOCK|jR!l@syH | LOCK|Cvf | $142B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|KJ>@^^T% | LOCK|^@ | $43B | |||
| Agilent Technologies Inc
A
| LOCK|Y@<!lF! | LOCK|MM | $42B | |||
| Waters Corp
WAT
| LOCK|$m!N!#z | LOCK|N@ | $40B | |||
| IQVIA Holdings Inc
IQV
| LOCK|wjRkn&< | LOCK|%dV#^ | $39B | |||
| Illumina Inc
ILMN
| LOCK|f^x!qG | LOCK|pKxC@ | $29B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|^BgZjwS | LOCK|^vz>> | $28B | |||
| Quest Diagnostics Inc
DGX
| LOCK|tg@P$> | LOCK|wyH@ | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|mrt<t<w! | LOCK|q>YW@ | $26B |
United States